Deshpande Neha A, Coscia Lisa A, Gomez-Lobo Veronica, Moritz Michael J, Armenti Vincent T
Harvard Medical School, Boston, MA.
National Transplantation Pregnancy Registry, Gift of Life Institute, Philadelphia, PA.
Rev Obstet Gynecol. 2013;6(3-4):116-25.
Successful pregnancy outcomes are possible among all solid organ transplant recipients. Patients should be fully counseled regarding the potential adverse fetal outcomes, including prematurity and low birth weight. Transplant recipients are at an increased risk for both maternal and neonatal complications and should be seen by a high-risk obstetrician in conjunction with their transplant teams. Ideally, preconception counseling begins during the pretransplantation evaluation process. Initiating contraception early after transplantation is ideal, and long-acting reversible methods such as intrauterine devices and subdermal implants may be preferred. Pregnancy should be avoided for at least 1 year after transplantation to limit the potential risks of early pregnancy that may adversely affect both allograft function and fetal well-being. Hypertension, diabetes, and infection should be monitored and treated to minimize fetal risks during pregnancy. Maintenance of current immunosuppression is usually recommended, with the exception of mycophenolic acid products, which (when possible) should be discontinued before conception and replaced with an alternative medication. Throughout pregnancy, immunosuppression must be maintained at appropriate dosing to avoid graft rejection. During labor and delivery, cesarean delivery should be performed for obstetric reasons only. A multidisciplinary team should manage pregnant transplant recipients before, during, and following pregnancy. Breastfeeding and long-term in utero exposure to immunosuppressants for offspring of transplant recipients continue to require further investigation but have been encouraged by recent reports. Continued reporting of post-transplantation pregnancy outcomes to the National Transplantation Pregnancy Registry is highly encouraged.
所有实体器官移植受者都有可能获得成功的妊娠结局。应向患者充分咨询潜在的不良胎儿结局,包括早产和低出生体重。移植受者发生母体和新生儿并发症的风险增加,应由高危产科医生联合其移植团队进行诊治。理想情况下,孕前咨询应在移植前评估过程中开始。移植后尽早开始避孕是理想的,长效可逆方法如宫内节育器和皮下植入物可能更受青睐。移植后应避免妊娠至少1年,以限制可能对同种异体移植功能和胎儿健康产生不利影响的早期妊娠潜在风险。应监测和治疗高血压、糖尿病和感染,以尽量降低孕期胎儿风险。通常建议维持当前的免疫抑制治疗,但霉酚酸类产品除外,此类产品(如有可能)应在受孕前停用,并换用其他药物。在整个孕期,必须维持适当剂量的免疫抑制治疗以避免移植物排斥反应。在分娩时,剖宫产仅应出于产科原因进行。多学科团队应在妊娠前、妊娠期间和妊娠后管理妊娠移植受者。移植受者的后代进行母乳喂养以及长期子宫内暴露于免疫抑制剂仍需进一步研究,但最近的报告对此表示支持。强烈鼓励继续向国家移植妊娠登记处报告移植后妊娠结局。